Slides
Page 1
Investor Day 2026: The Next Era of Model-informed Drug Development INTEGRATED. AI -ENABLED. CLOUD -READY. NASDAQ: SLP
Page 2
SAFE HARBOR STATEMENT Except for historical information, the matters discussed in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Words like “believe,” “will”, “can”, “expect,” “anticipate” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Statements include but are not limited to those relating to fiscal year 2026 guidance, expected revenue growth and mix, margins and profitability, demand for our services and software, pricing actions, client spending levels and long-term business strategies. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our operational structure, our ability to maintain our competitive advantages and commercialize AI and cloud-enabled solutions, evolving regulatory and data privacy standards governing AI technologies, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. This presentation includes certain financial measures not presented in accordance with generally accepted accounting principles (“GAAP”) such as Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Diluted EPS and certain ratios and other metrics derived there from. These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under GAAP. You should be aware that the presentation of these measures may not be comparable to similarly-titled measures used by other companies. We believe (i) these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends; and (ii) that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in and in comparing financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are set forth in the appendix to this presentation. NON -GAAP FINANCIAL MEASURES 02
Page 3
Agenda Lorem ipsum dolor sit amet consectetur Introduction Industry Environment & Priorities Product & Technology Roadmap Scientific Services Roadmap Closing Remarks Q&A 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 03 04 10 19 66 72 76
Page 4
INTRODUCTION | VISION, MISSION, VALUES To improve quality of life through innovative solutions. To create value for our customers by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. Innovation Pursuing novel and creative solutions to positively impact the world. Respect Promoting a diverse workforce and inclusive culture, while serving our communities. Integrity Thoroughly and accurately communicating with uncompromised truth and honesty. Commitment Providing quality products and exceptional services that deliver value to our partners and the people we serve. Wellness Prioritizing wellness as an essential component in fostering a healthy and productive environment. Vision: Mission: Values: 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 04
Page 5
Industry leader in expanding suite of biosimulation, clinical operations and medical communications Strength in science and technology with vision for the future Trusted partner of biopharma industry and regulatory bodies Long track record of growth and profitability INTRODUCTION Company Highlights 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 05 Category Leadership Science & Technology Trusted Partnerships Science & Technology 1 2 3 4
Page 6
INTRODUCTION 30 years of growth FY05 FY14 FY20 FY23 FY26 Acquired Cognigen Expansion into PKPD services Acquired DILIsym Expansion into QSP software & services Acquired Immunetrics Expanded QSP offering with additional TA solutions Acquired Lixoft Expanded PKPD offering with software Acquired Pro-ficiency Expansion into ClinOps & Medical Communications $4B TAM expansion with solutions across entire biopharma value chain Standardized software platform across biopharma value chain FY96 FY97 FY98 FY17 FY24 Founded ADMET Predictor 1.0 released GastroPlus 1.0 released Listed on Nasdaq 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 06
Page 7
INDUSTRY ENVIRONMENT & PRIORITIES Complementary Solutions Orchestration Grounded Intelligence Composition Scientific Engines GastroPlus® MonolixSuite ADMET Predictor® DILIsym® Thales 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 07 Discovery Development Clinical Ops. Commercialization
Page 8
INDUSTRY ENVIRONMENT & PRIORITIES TAM/Industry Growth $12.5B TOTAL S+ TAM 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 08 TODAY Clinical Trial Technology & Services: $25.8B TODAY | $60.8B 2030 $27.2B TOTAL S+ TAM 2030 Biosimulation Clinical Trial Training Medical Comm. $3.9B $1.5B $7.1B 17% 19% 6% TAM Today CAGR SOURCE: Grand View Research, Growth Market Reports, LP Information
Page 9
Jill Fiedler-Kelly PRESIDENT OF SERVICES SOLUTIONS Josh Fohey CHIEF OPERATIONS OFFICER John DiBella CHIEF REVENUE OFFICER INDUSTRY ENVIRONMENT & PRIORITIES Executive Team Shawn O’Connor CHIEF EXECUTIVE OFFICER Jonathan Chauvin CO -CHIEF PRODUCT & TECHNOLOGY OFFICER Erik Guffrey CO -CHIEF PRODUCT & TECHNOLOGY OFFICER Will Frederick CHIEF FINANCIAL OFFICER Viera Lukacova CHIEF SCIENTIFIC OFFICER 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 09
Page 10
ROADMAP Industry Environment & Priorities John DiBella CHIEF REVENUE OFFICER 10
Page 11
Inflection point Empirical, siloed, slow INDUSTRY ENVIRONMENT & PRIORITIES Industry at an inflection point 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 11 Integrated, model informed
Page 12
INDUSTRY ENVIRONMENT & PRIORITIES Evolution of modeling in drug development Model Supported Model Informed Modeling has shifted from supplemental → central to pipeline decision-making 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 12 Model Supported Model Informed Model Based
Page 13
INDUSTRY ENVIRONMENT & PRIORITIES Pressures accelerating the shift Economic ScientificTechnological NAMs & MIDD 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 13
Page 14
INDUSTRY ENVIRONMENT & PRIORITIES Regulatory momentum driving adoption Earlier More decisions Explainable AI 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 14
Page 15
INDUSTRY ENVIRONMENT & PRIORITIES Customers are redesigning how they work Orchestration Grounded Intelligence Composition Scientific Engines GastroPlus® MonolixSuite ADMET Predictor® DILIsym® Thales 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 15 Discovery Development Clinical Ops. Commercialization
Page 16
INDUSTRY ENVIRONMENT & PRIORITIES S+ role: From tool providers to ecosystem partner AI, DATA, ENABLEMENT SOFTWARE & SERVICES SCIENCE Model Supported Model Based Model Informed 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 16
Page 17
AI, DATA, ENABLEMENT SOFTWARE & SERVICES SCIENCE INDUSTRY ENVIRONMENT & PRIORITIES Connecting the ecosystem to customer growth 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 17
Page 18
INDUSTRY ENVIRONMENT & PRIORITIES Takeaways Integration is inevitable Adoption is accelerating Partnership matters 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 18
Page 19
ROADMAP Product & Technology 19
Page 20
PRODUCT & TECHNOLOGY Three decades of validated science Jonathan Chauvin CO -CHIEF PRODUCT & TECHNOLOGY OFFICER 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 20
Page 21
GastroPlus® MonolixSuite ADMET Predictor® DILIsym® PRODUCT & TECHNOLOGY Engines trusted when decisions matter Thales 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 21
Page 22
PRODUCT & TECHNOLOGY Now spanning discovery to commercialization Discovery Development Clinical Ops Commercialization 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 22
Page 23
PRODUCT & TECHNOLOGY Engines that remain authoritative Deterministic 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 23 Reproducible Validated
Page 24
“What can I trust?" PRODUCT & TECHNOLOGY 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 24
Page 25
Without validated science, nothing scales. PRODUCT & TECHNOLOGY 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 25
Page 26
PRODUCT & TECHNOLOGY Engines entering a new era Composability Scale Intelligence We live here 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 26
Page 27
PRODUCT & TECHNOLOGY AI-orchestrated ecosystem 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 27
Page 28
PRODUCT & TECHNOLOGY Customers aren't asking for more tools 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 28
Page 29
PRODUCT & TECHNOLOGY More than isolated results 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S Trustworthy AI Integrated workflows Reproducibility Automation Modeling to operational decisions 29 Modeling to operational decisions
Page 30
PRODUCT & TECHNOLOGY AI + cloud + validated science 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 30
Page 31
PRODUCT & TECHNOLOGY From federation of tools to unified ecosystem 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 31
Page 32
PRODUCT & TECHNOLOGY Why this is differentiated AI-first vs. weak validation Cloud-first vs. fragmented modeling Engine-first vs. no unifying workflow layer 32
Page 33
PRODUCT & TECHNOLOGY Architecture Overview Erik Guffrey CO -CHIEF PRODUCT & TECHNOLOGY OFFICER 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 33
Page 34
PRODUCT & TECHNOLOGY Engines remain authoritative 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 34
Page 35
PRODUCT & TECHNOLOGY One structural language across products Together, they turn individual tools into a coherent system. 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 35
Page 36
PRODUCT & TECHNOLOGY Deterministic. Regulatory-aligned. Evolving. 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S Scientific engines 36
Page 37
PRODUCT & TECHNOLOGY Interoperable. Orchestratable. Shared patterns. 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S Scientific engines Composition 37
Page 38
PRODUCT & TECHNOLOGY AI grounded in validated science 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S Grounded intelligence Scientific engines Composition 38
Page 39
PRODUCT & TECHNOLOGY End-to-end workflow automation Orchestration Grounded intelligence Scientific engines Composition 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 39
Page 40
PRODUCT & TECHNOLOGY S+ Cloud: Scale, collaboration, governance – same architecture 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 40
Page 41
PRODUCT & TECHNOLOGY Open patterns; interoperable workflows 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 41
Page 42
PRODUCT & TECHNOLOGY Opportunities unlocked 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 42
Page 43
PRODUCT & TECHNOLOGY What took weeks now takes hours 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 43
Page 44
PRODUCT & TECHNOLOGY Traceability and reproducibility 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 44
Page 45
PRODUCT & TECHNOLOGY Collaboration with computation in the loop 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 45
Page 46
PRODUCT & TECHNOLOGY Architecture compounds value 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 46
Page 47
PRODUCT & TECHNOLOGY Explainable. Constrained. Anchored. 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 47
Page 48
PRODUCT & TECHNOLOGY One chain from discovery to commercialization 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 48
Page 49
PRODUCT & TECHNOLOGY Roadmap 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 49
Page 50
PRODUCT & TECHNOLOGY Foundation Unification Ecosystem 12 MO 12-36 MO 36+ MO 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 50
Page 51
More engines exposed AI copilots embedded PRODUCT & TECHNOLOGY Near-term: Completing the backbone S+ Cloud identity & workspaces Early cross product workflows emerging 12 MO Declarative pipelines standard 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 51
Page 52
Cross-engine templates mature AI expands across modeling + readiness Scientific + operation workflows converge Multi-product workflows become standard PRODUCT & TECHNOLOGY Mid-term: Modeling + operations in one language 12-36 MO 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 52
Page 53
Discovery Development Clinical Ops PRODUCT & TECHNOLOGY Long-term ecosystem AI across disciplines + cloud-scale compute 36+ MO Continuous lifecycle feedback loop 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 53
Page 54
PRODUCT & TECHNOLOGY Business impact Jonathan Chauvin CO -CHIEF PRODUCT & TECHNOLOGY OFFICER 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 54
Page 55
2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 55 PRODUCT & TECHNOLOGY Accelerating science strengthens our business
Page 56
PRODUCT & TECHNOLOGY From tools to platform relationships New revenue opportunities 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S Workflow –based products / portfolio workflow packages Cloud collaboration features Cross-product bundles Tokenized usage models Premium AI copilots ClinOps + commercialization modules 56
Page 57
PRODUCT & TECHNOLOGY Value compounds when connected Customer lifetime value Higher adoption within each account Broader enterprise expansion Deeper integration into customer workflows Longer, more resilient customer relationships 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 57
Page 58
PRODUCT & TECHNOLOGY Pricing follows value Pricing and packaging evolution 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 58 Engines remain as-is Optional premium AI Composition as a surface Cloud add-ons
Page 59
PRODUCT & TECHNOLOGY 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S R&D Products Services 59
Page 60
PRODUCT & TECHNOLOGY Why we win 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S Scientific core1 Architecture2 Orchestration3 Trustworthy AI4 Scalable ecosystem5 60
Page 61
PRODUCT & TECHNOLOGY Validated engines, training & logic 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S Scientific core 61
Page 62
PRODUCT & TECHNOLOGY Engines authoritative; AI grounded Architecture advantage Interoperable workflows Grounded AI Optional cloud scale Integrated operational systems 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 62
Page 63
PRODUCT & TECHNOLOGY Declarative patterns; reusable pipelines Solving the workflow problem 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 63
Page 64
PRODUCT & TECHNOLOGY Explainable. Constrained. Anchored. Inside validated scientific frames. 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S Trustworthy AI 64
Page 65
PRODUCT & TECHNOLOGY Sales across teams & lifecycle 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S Ecosystem scale 65
Page 66
ROADMAP Scientific Services Jill Fiedler-Kelly PRESIDENT OF SERVICES SOLUTIONS 66
Page 67
SCIENTIFIC SERVICES De-risking client development programs Modeling and simulation services reduce uncertainty. 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 67
Page 68
SCIENTIFIC SERVICES Our core consulting solutions PBPK & PBBM Mechanistic insight that reduces cost and clinical burden QSP & QST Mechanistic disease modeling for efficacy & safety prediction Clinical Pharmacology & Pharmacometrics Decision-quality PK/PD & exposure- response to support dose selection & regulatory submission Quality, regulatory leadership & strategic expertise Commercialization services Extending insight beyond research & development Guidance from trusted experts working in a validated system 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 68
Page 69
Integrated cross-solution support offerings Case study 2 PopPK + PBPK + QSP Faster formulation Case study 1 QSP + CPP FIH & Phase 2 Optimization SCIENTIFIC SERVICES 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 69
Page 70
SCIENTIFIC SERVICES Alignment with FDA's NAM roadmap Services and software solutions support a reduction in animal testing. 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 70
Page 71
CLOSING REMARKS Outcomes we support 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S Reducing cost, time, and uncertainty Relevance Durability Competitive advantage 71
Page 72
We are an industry leader rooted in science, with the technology and vision to shape the next era of drug development. CLOSING REMARKS Shaping the next era Trusted by the biopharma industry and global regulatory bodies 30-year track record of growth and profitability 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 72
Page 73
2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S Integrated science Unified ecosystem CLOSING REMARKS MIDD is now core R&D infrastructure Trusted by the biopharma industry and global regulatory bodies 30-year track record of growth and profitability 73
Page 74
CLOSING REMARKS Powering the next decade of MIDD Shawn O’Connor CHIEF EXECUTIVE OFFICER 74
Page 75
Science + Cloud + AI + Services = One coherent platform CLOSING REMARKS 2 0 2 6 I N V E S T O R D A Y | S I M U L A T I O N S P L U S 75
Page 76
Q&A 76